18:04:10 Europe / Stockholm

Prenumeration

2024-04-19 17:10:00

Estimates compiled by Modular Finance on behalf of XVIVO Perfusion.

Number of contributors: 6 (all of which have been updated or confirmed before the report)

KPIQ1 2024E
Net sales (MSEK)165
Organic growth in local currency (%)15.8
Gross profit (MSEK)123
EBIT (MSEK)9
EBITDA (MSEK)26
Net profit (MSEK)8
Earnings per share (SEK)0.25
Net sales per segment:
Thoracic (MSEK)103
Abdominal (MSEK)40
Services (MSEK)22

XVIVO Perfusion’s Q1 report will be released on Wednesday, 24 April, at 07:30 am CEST.